MaxCyte, Inc. Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised
MaxCyte, Inc. (MXCT) reported Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised of $34.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans · last filed 2026-08-13
- MaxCyte, Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2025-12-31 was $90.00K, a 53.61% decline year-over-year.
- MaxCyte, Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2025-09-30 was $0.00.
- MaxCyte, Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2024-12-31 was $194.00K.
- MaxCyte, Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2024-09-30 was $0.00.
- MaxCyte, Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2025 was $224.00K, a 51.20% decline from fiscal 2024.
- MaxCyte, Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2024 was $459.00K, a 70.63% increase from fiscal 2023.
- MaxCyte, Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2023 was $269.00K.
| Period end | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 3 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 6 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 9 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 12 month |
|---|---|---|---|---|
| 2026-06-30 | $34.00K 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $90.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $90.00K derived: sum of 2 quarters · filed 2026-03-25 | $224.00K 10-K · filed 2026-03-25 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $134.00K 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | $134.00K 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $194.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $194.00K derived: sum of 2 quarters · filed 2026-03-25 | $459.00K 10-K · filed 2026-03-25 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $265.00K 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | $265.00K 10-Q · filed 2025-08-06 | |||
| 2023-12-31 | $269.00K 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |